Cytochrome p-450 polymorphisms and response to clopidogrel.

[1] Sabatine M.S.(2005)Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study JAMA 294 1224-1232

[2] Cannon C.P.(2005)Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation N Engl J Med 352 1179-1189

[3] Gibson C.M.(2003)Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2908-2913

[4] Sabatine M.S.(2007)Variable response to clopidogrel in patients with coronary artery disease Semin Thromb Hemost 33 196-202

[5] Cannon C.P.(2006)Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2244-2247

[6] Gibson C.M.(2007)Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients Pharmacogenet Genomics 17 1057-1064

[7] Gurbel P.A.(2007)Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel J Thromb Haemost 5 2429-2436

[8] Bliden K.P.(2009)Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 363-375

[9] Hiatt B.L.(2006)Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy Platelets 17 250-258

[10] O’Connor C.M.(2006)Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel CMAJ 174 1715-1722

[1] Sabatine M.S.(2005)Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study JAMA 294 1224-1232

[2] Cannon C.P.(2005)Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation N Engl J Med 352 1179-1189

[3] Gibson C.M.(2003)Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2908-2913

[4] Sabatine M.S.(2007)Variable response to clopidogrel in patients with coronary artery disease Semin Thromb Hemost 33 196-202

[5] Cannon C.P.(2006)Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2244-2247

[6] Gibson C.M.(2007)Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients Pharmacogenet Genomics 17 1057-1064

[7] Gurbel P.A.(2007)Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel J Thromb Haemost 5 2429-2436

[8] Bliden K.P.(2009)Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 363-375

[9] Hiatt B.L.(2006)Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy Platelets 17 250-258

[10] O’Connor C.M.(2006)Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel CMAJ 174 1715-1722